Monte Rosa Therapeutics, Inc. (GLUE)
14.38
+0.16
(+1.13%)
USD |
NASDAQ |
Sep 03, 16:00
14.38
0.00 (0.00%)
After-Hours: 20:00
Monte Rosa Therapeutics Research and Development Expense (TTM) : 162.57M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 162.57M |
| March 31, 2026 | 145.04M |
| December 31, 2025 | 133.14M |
| September 30, 2025 | 130.06M |
| June 30, 2025 | 120.99M |
| March 31, 2025 | 118.46M |
| December 31, 2024 | 113.44M |
| September 30, 2024 | 101.93M |
| June 30, 2024 | 102.88M |
| March 31, 2024 | 104.58M |
| December 31, 2023 | 105.05M |
| September 30, 2023 | 101.95M |
| Date | Value |
|---|---|
| June 30, 2023 | 94.24M |
| March 31, 2023 | 85.32M |
| December 31, 2022 | 76.50M |
| September 30, 2022 | 71.64M |
| June 30, 2022 | 67.40M |
| March 31, 2022 | 62.81M |
| December 31, 2021 | 55.02M |
| September 30, 2021 | 47.34M |
| June 30, 2021 | 38.11M |
| March 31, 2021 | 28.72M |
| December 31, 2020 | 23.47M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Nurix Therapeutics, Inc. | 332.34M |
| Gilead Sciences, Inc. | 5.943B |
| Ironwood Pharmaceuticals, Inc. | 86.86M |
| Capricor Therapeutics, Inc. | 98.66M |
| Cue Biopharma, Inc. | 76.97M |